4
Changes in Ownership
ArriVent BioPharma, Inc. Filed Acc 0001104659-25-067928
Chief Operating Officer acquired 11,153 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| LaChapelle Robin Chief Operating Officer | 2025-07-11 | Option exercise | +2,050 | $2.28 | $4,674 | 126,633 | D: show line 1 in the form |
| LaChapelle Robin Chief Operating Officer | 2025-07-11 | Option exercise | +2,600 | $2.28 | $5,928 | 129,233 | D: show line 2 in the form |
| LaChapelle Robin Chief Operating Officer | 2025-07-11 | Option exercise | +6,503 | $2.28 | $14,827 | 135,736 | D: show line 3 in the form |
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| LaChapelle Robin Chief Operating Officer | 2025-07-11 | Option exercise · Stock Option (right to buy) | −2,050 | 410 | D: show line 4 in the form | ||
| LaChapelle Robin Chief Operating Officer | 2025-07-11 | Option exercise · Stock Option (right to buy) | −2,600 | 12,873 | D: show line 5 in the form | ||
| LaChapelle Robin Chief Operating Officer | 2025-07-11 | Option exercise · Stock Option (right to buy) | −6,503 | 6,370 | D: show line 6 in the form |
Loading xslF345X05/tm2520948-1_4seq1.xml…